Clinical, Biological and Molecular Aspects of COVID-19
Autor: | Paul C. Guest |
---|---|
EAN: | 9783030592615 |
eBook Format: | |
Sprache: | Englisch |
Produktart: | eBook |
Veröffentlichungsdatum: | 03.03.2021 |
Kategorie: | |
Schlagworte: | novel coronavirus;respiratory distress syndrome;health care workers;hospitalization outcomes;chest imaging;mortality;HRCT;vaccine;pregnancy;heart disease;stress;statin therapy;procalcitonin;antigiotensin-converting enzyme;anxiety;depression;acute kid |
181,89 €*
Versandkostenfrei
Die Verfügbarkeit wird nach ihrer Bestellung bei uns geprüft.
Bücher sind in der Regel innerhalb von 1-2 Werktagen abholbereit.
The novel coronavirus 2019 (COVID-19) has caused a serious global pandemic in just eight months. Nearly every country and territory in the world has been affected by the virus. The virulence and infection rate of the virus are profound, and has required extreme social distancing measures across the globe in order to prevent overwhelming the healthcare services and hospitals. COVID-19 appears to have the greatest effects on elderly individuals and those who have co-morbid diseases, such as heart disease, asthma, and diabetes. As the peak begins to slow in many countries, the death rates remain high amidst justified fears of a second wave. A rapid worldwide mobilization has begun to identify effective treatments and develop vaccines.
This new volume will increase readers' understanding of the ongoing COVID-19 pandemic through a series of chapters that address these concerns. Leading experts will discuss the effects of the virus in cases of co-morbidities, new treatment approaches, mental health aspects of the pandemic, and convey the results of survey studies. The book will be an excellent resource for researchers studying virology, metabolic diseases, respiratory disorders, and clinical scientists, physicians, drug companies, and healthcare services and workers.
Dr. Paul C. Guest, Ph.D, is a scientific researcher/writer with 37 years of experience in the fields of metabolic and neurological disorders. This includes experience in both academia and the pharmaceutical industry with the majority of time spent at the University of Cambridge and Merck Sharp & Dohme in the United Kingdom. He has also been affiliated with the University of Campinas in Sao Paulo Brazil since 2015, still focused on advancing the field of biomarkers for neurological disorders such as schizophrenia and Alzheimer's disease, and more recently in the area of anti-aging research.